drugset / Trial / NCT05954624

Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid

NCT05954624

Phase 1 Completed 49 enrolled Guangdong Raynovent Biotech Co., Ltd
RandomizedSequentialOpen-labelBasic science

Summary

The drug-drug interaction study had been designed to investigate the effect of ZSP1273 on the pharmacokinetics of digoxin, Rosuvastatin and the effect of Itraconazole and Probenecid on the pharmacokinetics of ZSP1273

Timeline

Start
2023-07-10
Primary completion
2023-11-20
Completion
2023-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified 0.25 mg Oral
Subject Itraconazole Small molecule 200 mg Oral
Subject Onradivir Small molecule 600 mg Oral
Subject Probenecid Small molecule 500 mg Oral
Subject Rosuvastatin Small molecule 10 mg Oral

Indications

No indication recorded.